Cetrorelix (Cetrotide)

Overview

Cetrorelix (brand name Cetrotide) is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used primarily in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation. Unlike GnRH agonists such as leuprolide, which require weeks of continuous administration to achieve pituitary suppression through receptor downregulation, cetrorelix produces immediate, competitive blockade of pituitary GnRH receptors, resulting in rapid and dose-dependent suppression of both LH and FSH secretion without an initial hormonal flare [1][17][21].

Cetrorelix was developed by Asta Medica AG (later acquired by Baxter, then Merck KGaA) in collaboration with reproductive endocrinology pioneer Andrew V. Schally. It received European Medicines Agency (EMA) approval on April 13, 1999, and United States Food and Drug Administration (FDA) approval on August 11, 2000, under the brand name Cetrotide. At the time of FDA approval, Asta Medica signed a co-marketing agreement with Serono (now EMD Serono, a division of Merck KGaA) for distribution in the United States [3][18].

The FDA-approved indication is limited to inhibition of premature LH surges in women undergoing controlled ovarian stimulation for IVF. However, cetrorelix has been extensively investigated in clinical trials for endometriosis, uterine fibroids, benign prostatic hyperplasia (BPH), and hormone-sensitive cancers, demonstrating the broader therapeutic potential of GnRH antagonism [7][8][9].

Type

GnRH antagonist (synthetic decapeptide)

Molecular Weight

1431.06 Da (anhydrous free base)

Molecular Formula

C70H92ClN17O14

Sequence

Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2

Modifications vs Native GnRH

D-amino acid substitutions at positions 1, 2, 3, 6, and 10

Half-life (0.25 mg)

~5 h (single dose); ~20.6 h (multiple doses)

Half-life (3 mg)

~62.8 h (single dose)

Bioavailability

85% (subcutaneous)

Routes

Subcutaneous injection

FDA Approval

August 11, 2000 (IVF indication only)

EMA Approval

April 13, 1999

Developer / Marketer

Asta Medica / Merck Serono (EMD Serono)

Molecular Structure and Chemistry

Amino Acid Sequence and Modifications

Cetrorelix is a synthetic decapeptide analog of native GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) with five amino acid substitutions at positions 1, 2, 3, 6, and 10. Its full chemical name is acetyl-D-3-(2'-naphthyl)-alanine-D-4-chlorophenylalanine-D-3-(3'-pyridyl)-alanine-L-serine-L-tyrosine-D-citrulline-L-leucine-L-arginine-L-proline-D-alanine-amide, expressed in shorthand notation as [1][3]:

Ac-D-Nal(2)-D-Cpa-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2

The molecular formula is C70H92ClN17O14, with a molecular weight of 1431.06 Da (calculated as the anhydrous free base). The commercial formulation is supplied as cetrorelix acetate [3].

Design Rationale for Amino Acid Substitutions

Each of the five non-natural amino acid substitutions serves a specific pharmacological purpose [1][10][17]:

1. Position 1 (D-Nal replacing pGlu): D-3-(2'-naphthyl)-alanine introduces a bulky hydrophobic group that enhances receptor binding affinity while converting agonist activity to antagonist activity
2. Position 2 (D-Cpa replacing His): D-4-chlorophenylalanine eliminates the histidine residue critical for receptor activation, further ensuring antagonist properties
3. Position 3 (D-Pal replacing Trp): D-3-(3'-pyridyl)-alanine replaces tryptophan with a pyridyl analog that maintains binding affinity while abolishing intrinsic activity
4. Position 6 (D-Cit replacing Gly): D-citrulline replaces the achiral glycine, conferring resistance to enzymatic cleavage at the Gly6-Leu7 bond and reducing histamine-releasing potential compared to earlier antagonists containing D-Arg6
5. Position 10 (D-Ala-NH2 replacing Gly-NH2): D-alanine amide protects against C-terminal carboxypeptidase degradation, extending the biological half-life

The introduction of D-citrulline at position 6 was a particularly important advancement in GnRH antagonist design. Earlier generation antagonists containing D-arginine or other basic residues at this position caused clinically significant histamine release and anaphylactoid reactions, limiting their utility. The neutral ureido side chain of citrulline dramatically reduced mast cell degranulation while preserving high receptor binding affinity [1][12][21].

Mechanism of Action

Competitive GnRH Receptor Blockade

Cetrorelix binds competitively to GnRH type I receptors (GnRH-R) on anterior pituitary gonadotroph cells, directly preventing native GnRH from activating these receptors. Unlike GnRH agonists, cetrorelix does not activate the Gq/11-phospholipase C signaling cascade and therefore does not stimulate gonadotropin release at any point during treatment [10][17][21].

The key mechanistic features of cetrorelix action include:

• Immediate onset: LH suppression begins within approximately 1 hour after a 3 mg dose and within 2 hours after a 0.25 mg dose [3][23]
• No flare effect: Unlike GnRH agonists, there is no initial surge of LH, FSH, or sex steroids, making cetrorelix suitable for situations requiring rapid gonadotropin suppression [1][17]
• Dose-dependent suppression: The degree and duration of gonadotropin suppression are directly proportional to the administered dose [3][14]
• Preferential LH suppression: Cetrorelix exerts a more pronounced suppressive effect on LH than on FSH, which is advantageous in IVF settings where some basal FSH activity supports ongoing follicular development [3][23]
• Rapid reversibility: Gonadotropin secretion resumes promptly upon drug clearance, allowing precise control of the hormonal milieu during IVF cycles [1][2]

Molecular Pharmacology at the Receptor Level

At the molecular level, cetrorelix occupies the same binding pocket on the GnRH receptor as native GnRH but fails to induce the conformational change required for G-protein coupling and signal transduction. The D-amino acid substitutions at positions 1, 2, and 3 are primarily responsible for converting agonist activity to pure antagonism, while the modifications at positions 6 and 10 enhance binding affinity and metabolic stability [10][21].

Pharmacokinetics

Cetrorelix demonstrates pharmacokinetic properties well-suited to its clinical application in IVF protocols [3][13][15]:

| Parameter | 0.25 mg SC | 3 mg SC | |-----------|------------|---------| | Bioavailability | 85% | 85% | | Tmax | 1-2 hours | 1-2 hours | | Half-life (single dose) | ~5 hours | ~62.8 hours | | Half-life (multiple doses) | ~20.6 hours | N/A | | Protein binding | 86% | 86% | | Volume of distribution | ~1 L/kg | ~1 L/kg |

Absorption and Distribution

Following subcutaneous injection, cetrorelix is rapidly absorbed with peak plasma concentrations achieved within 1-2 hours. The absolute bioavailability is 85%, indicating minimal first-pass degradation at the injection site. In vitro plasma protein binding is 86%, and the volume of distribution following intravenous administration of 3 mg is approximately 1 L/kg [3][13].

Metabolism and Elimination

Cetrorelix demonstrates notable stability against phase I and phase II hepatic metabolism in vitro. The primary route of biotransformation is peptidase-mediated cleavage, with the (1-4) fragment being the predominant metabolite. Approximately 2-4% of the administered dose is excreted unchanged in urine, while 5-10% appears in bile as cetrorelix and four metabolites [3][13].

The half-life is strongly dose-dependent: a single 0.25 mg dose yields a half-life of approximately 5 hours, while multiple 0.25 mg daily doses extend the effective half-life to 20.6 hours through accumulation kinetics. The 3 mg single dose achieves a notably long half-life of 62.8 hours, providing a therapeutic window of at least 96 hours (4 days) of effective LH suppression from a single injection [3][13].

Clinical Applications

IVF and Assisted Reproductive Technology (FDA-Approved Indication)

The primary and only FDA-approved use of cetrorelix is prevention of premature LH surges during controlled ovarian stimulation (COS) for in vitro fertilization and embryo transfer (IVF-ET) [3][4].

The Problem of Premature LH Surge

During ovarian stimulation with exogenous gonadotropins, rising estradiol levels from multiple developing follicles can trigger a premature endogenous LH surge via positive feedback on the hypothalamus and pituitary. This premature surge causes premature luteinization or ovulation, resulting in cycle cancellation in 20-30% of unstimulated cycles and significantly reducing the number of retrievable oocytes [2][23].

GnRH Antagonist Protocol

Cetrorelix is administered during the mid-to-late follicular phase of stimulated IVF cycles using one of two established protocols [3][5][6]:

Multiple-Dose Protocol (0.25 mg daily):

• Cetrorelix 0.25 mg is injected subcutaneously once daily, typically beginning on stimulation day 5-6 or when the leading follicle reaches 14 mm in diameter
• Daily injections continue until the day of human chorionic gonadotropin (hCG) trigger administration, including the day of hCG
• This protocol provides flexible, day-by-day control of LH suppression
• The 0.25 mg dose was established as the minimal effective dose in Phase 2 studies [3]

Single-Dose Protocol (3 mg):

• A single subcutaneous injection of 3 mg cetrorelix is administered on stimulation day 7-8
• This dose provides effective LH suppression for at least 96 hours (4 days)
• If hCG trigger has not been administered within 4 days of the 3 mg injection, daily 0.25 mg cetrorelix injections are initiated and continued until hCG administration
• In Phase 3 trials, approximately 73% of patients required only the single 3 mg injection [3][5]

Clinical Outcomes

Pivotal trials demonstrated that cetrorelix effectively prevented premature LH surges in virtually all treated patients. The European Phase III trial comparing cetrorelix antagonist protocol to buserelin long agonist protocol showed comparable clinical pregnancy rates (22.4% vs. 25.5%) with significantly shorter treatment duration and fewer injections in the antagonist arm [6].

A comprehensive Cochrane review (2016) of GnRH antagonist versus agonist protocols in IVF concluded that while live birth rates were comparable, antagonist protocols offered important practical advantages: shorter stimulation duration, lower total gonadotropin dose, fewer injections, greater patient convenience, and a significantly reduced incidence of ovarian hyperstimulation syndrome (OHSS) [4].

OHSS Prevention

The use of GnRH antagonist protocols (including cetrorelix-based regimens) has become a key strategy in preventing ovarian hyperstimulation syndrome, a potentially life-threatening iatrogenic complication of IVF [4][24][25].

GnRH antagonist protocols reduce OHSS risk through two mechanisms:

1. Lower overall hormonal stimulation: The antagonist protocol's shorter duration and lower gonadotropin requirements produce fewer supraphysiologic estradiol peaks
2. GnRH agonist trigger compatibility: When a GnRH antagonist (cetrorelix) is used for LH suppression, final oocyte maturation can be triggered with a GnRH agonist bolus instead of hCG, inducing an endogenous LH/FSH surge of shorter duration. This dramatically reduces the risk of OHSS compared to hCG triggering, because hCG's long half-life sustains luteotropic stimulation for days [4][22][25]

The ASRM guidelines (2023) recommend GnRH antagonist protocols over long agonist protocols for patients at elevated risk of OHSS, including those with polycystic ovary syndrome, high antral follicle counts, prior OHSS episodes, or low body weight [25]. A prospective randomized trial in PCOS patients demonstrated that the flexible GnRH antagonist protocol significantly reduced OHSS incidence compared to the long agonist protocol while maintaining comparable pregnancy rates [24].

Additionally, cetrorelix has been investigated as a secondary prevention measure when administered in the early luteal phase to patients showing signs of developing OHSS after oocyte retrieval, with evidence suggesting effective reduction in OHSS severity [25].

Endometriosis (Investigational)

Cetrorelix has been studied as a treatment for endometriosis, with the hypothesis that GnRH antagonists can suppress ovarian estrogen production — the primary driver of endometriotic implant growth — without the initial flare and prolonged recovery time associated with GnRH agonists [7][17].

In a clinical study, subcutaneous administration of cetrorelix 3 mg once weekly for 8 weeks induced regression of endometriotic implants, with improvement observed in 60% of cases (9 of 15 patients). Disease staging declined to stage II, and patients experienced significant symptomatic relief without the vasomotor side effects typically seen with GnRH agonist therapy [7].

The theoretical advantage of GnRH antagonist therapy for endometriosis is the potential for dose-dependent, partial suppression of estrogen — maintaining circulating estradiol above the threshold for bone protection (~30-50 pg/mL) while remaining below the threshold that stimulates endometriotic growth (~50-60 pg/mL). This "therapeutic window" concept could potentially enable longer treatment durations without add-back therapy [7][17]. However, development of cetrorelix for this indication was not pursued to regulatory approval, and newer oral GnRH antagonists (elagolix, relugolix combination therapy, linzagolix) have since been developed and approved for endometriosis [17].

Uterine Fibroids (Investigational)

Cetrorelix has been evaluated as a short-term presurgical treatment for uterine fibroids in several clinical studies [8].

A double-blind, placebo-controlled multicenter trial enrolled 109 premenopausal women with at least one uterine fibroid exceeding 4 cm in diameter. Patients received placebo or cetrorelix acetate at various dose regimens for 4 weeks prior to surgery. Mean reductions in uterine volume at day 29 were [8]:

| Treatment Group | Uterine Volume Reduction | |-----------------|--------------------------| | Placebo | 5.1% | | Cetrorelix 5 mg x 4 weekly | 15.6% | | Cetrorelix 10 mg x 4 weekly | 15.4% | | Cetrorelix 10 mg x 2 biweekly | 0.6% |

An earlier open-label study in 20 premenopausal women achieved a maximum fibroid size reduction of 33.5%. While these results demonstrated proof-of-concept, the magnitude of volume reduction was generally less than that achieved with GnRH agonists over 3-6 months, and the indication was not pursued to regulatory approval [8].

Benign Prostatic Hyperplasia (Investigational)

Cetrorelix was investigated for symptomatic BPH in a placebo-controlled dose-ranging Phase 2 study enrolling 140 patients. Three dosage regimens were tested: 5 mg weekly for 4 weeks, 10 mg biweekly for 2 doses, and 10 mg weekly for 4 weeks [9].

Key findings included:

• International Prostate Symptom Score (IPSS) improvements of 3-4 units at week 4 across active treatment groups
• Mean peak urinary flow rate increased from approximately 9 mL/s to approximately 13 mL/s
• Prostatic volume reduction of approximately 27%
• One study reported a 52.9% decline in IPSS and 46% improvement in quality-of-life scores
• Good tolerability at all cetrorelix dosages [9]

A sustained-release formulation (cetrorelix pamoate) was also evaluated, with intramuscular doses of 30-60 mg providing rapid symptomatic improvement sustained for 6 months. Despite promising Phase 2 results, development of cetrorelix for BPH was discontinued, and no GnRH antagonist is currently approved specifically for this indication [9].

Comparison with Other GnRH Antagonists

Cetrorelix vs. Ganirelix

Ganirelix (Orgalutran/Antagon) is the other widely used GnRH antagonist in IVF. Both are synthetic decapeptides with similar mechanisms, but they differ in structural details and some clinical outcomes [11][19]:

| Feature | Cetrorelix (Cetrotide) | Ganirelix (Orgalutran) | |---------|------------------------|------------------------| | Available doses | 0.25 mg and 3 mg | 0.25 mg only | | Single-dose option | Yes (3 mg) | No | | Dose protocols | Single-dose or multiple-dose | Multiple-dose only | | LH surge incidence (LH greater than or equal to 10 U/L) | 4.9% | 7.6% | | OHSS incidence | 0.4% | 1.1% | | Endometrial Type A morphology | 66.2% | 60.1% | | Live birth rate | 47.2% | 49.4% | | Histamine release potential | Moderate | Low-moderate |

A large retrospective cohort study (2025) comparing 7,873 cetrorelix-treated and 7,744 ganirelix-treated IVF/ICSI cycles found that cetrorelix demonstrated superior LH surge control with lower incidences of elevated LH, lower OHSS rates, and more favorable endometrial receptivity markers (higher Type A and lower Type C endometrial morphology). Live birth rates were comparable between the two agents [19].

Cetrorelix vs. Degarelix

Degarelix (Firmagon) is a GnRH antagonist approved for advanced prostate cancer rather than IVF. Key differences include [12][17]:

• Indication: Degarelix is FDA-approved (2008) for hormone-dependent prostate cancer; cetrorelix for IVF
• Histamine release: Degarelix has the lowest histamine-releasing capacity among GnRH antagonists due to its unique amino acid composition. In an ex vivo human skin model, histamine release ranked: cetrorelix (highest) followed by abarelix, ganirelix, and degarelix (lowest) [12]
• Duration of action: Degarelix depot (240 mg loading, then 80 mg monthly) provides sustained testosterone suppression for prostate cancer management
• Clinical context: Degarelix was specifically designed to avoid the histamine release problem that limited earlier GnRH antagonists in oncology settings requiring chronic dosing [12]

GnRH Antagonists vs. GnRH Agonists in IVF

The fundamental pharmacological distinction between cetrorelix and GnRH agonists (leuprolide, buserelin, triptorelin, nafarelin) used in IVF protocols is the mechanism of gonadotropin suppression [2][4][17]:

| Feature | GnRH Antagonist (Cetrorelix) | GnRH Agonist (e.g., Leuprolide) | |---------|------------------------------|----------------------------------| | Mechanism | Competitive receptor blockade | Receptor downregulation | | Onset of suppression | 1-2 hours | 2-3 weeks | | Initial flare | No | Yes (7-10 days) | | Stimulation duration | Shorter (8-9 days) | Longer (10-12 days) | | Total gonadotropin dose | Lower | Higher | | Number of injections | Fewer | More | | OHSS risk | Lower (OR 0.43) | Higher | | Compatibility with GnRH agonist trigger | Yes | No | | Patient convenience | Greater | Less | | Live birth rate | Comparable | Comparable |

Safety and Adverse Effects

Common Adverse Reactions

Cetrorelix demonstrates a favorable safety profile in its approved indication. The most frequently reported adverse effects in clinical trials include [3]:

• Injection site reactions (redness, erythema, bruising, itching, swelling): Usually transient, mild, and self-limiting
• Ovarian hyperstimulation syndrome: Reported at lower rates than with GnRH agonist protocols
• Nausea: Mild and generally transient
• Headache: Reported in a small percentage of patients

Serious but Rare Adverse Events

Post-marketing surveillance has identified the following rare adverse events [3]:

• Hypersensitivity reactions: Including anaphylactoid reactions, some occurring with the first dose. One case of severe anaphylaxis with cough, rash, and hypotension was reported after seven months of treatment
• Mild to moderate OHSS: Although less common than with agonist protocols, OHSS can still occur during ovarian stimulation with GnRH antagonist co-treatment

Histamine Release Considerations

Early-generation GnRH antagonists were limited by clinically significant histamine-releasing activity causing urticaria, flushing, and bronchospasm. Cetrorelix's incorporation of D-citrulline at position 6 (replacing the D-arginine found in earlier compounds) substantially reduced but did not eliminate histamine release potential. Among currently available GnRH antagonists, cetrorelix has a somewhat higher histamine-releasing capacity than ganirelix or degarelix, though clinically significant reactions remain rare at the low doses used in IVF [1][12][21].

Contraindications

Cetrorelix is contraindicated in patients with [3]:

• Known hypersensitivity to cetrorelix, extrinsic peptide hormones, or mannitol
• Known or suspected pregnancy
• Breastfeeding
• Severe renal impairment
• Postmenopausal women

Development History and Regulatory Timeline

| Year | Milestone | |------|-----------| | 1980s | Andrew V. Schally and colleagues synthesize cetrorelix (SB-75) as part of systematic structure-activity studies of GnRH antagonists | | 1990s | Asta Medica AG (Germany) develops cetrorelix for clinical use | | 1994 | First clinical demonstration of premature LH surge suppression during ovarian stimulation | | 1999 | European Medicines Agency (EMA) approves Cetrotide (April 13, 1999) | | 2000 | FDA approves Cetrotide for IVF indication (August 11, 2000); Asta Medica signs co-marketing deal with Serono | | 2001 | Asta Medica acquired by Baxter International | | 2002-2008 | Investigational studies for endometriosis, uterine fibroids, and BPH | | 2007 | Merck KGaA acquires Serono; Cetrotide marketing transitions to EMD Serono | | 2023 | FDA approves generic cetrorelix acetate (Sun Pharmaceutical Industries) |

Cetrorelix was designated internally as SB-75 (and later D-20761) during development. Its design was part of a broader research program led by Nobel laureate Andrew V. Schally aimed at creating GnRH antagonists with reduced histamine-releasing potential compared to first-generation compounds. The strategic replacement of basic amino acids (D-Arg, D-Lys) at position 6 with neutral residues like D-citrulline was the key breakthrough that made clinical application feasible [1][17][18].

Clinical Evidence Summary

| Study / Source | Year | Design | Key Finding | |----------------|------|--------|-------------| | Diedrich et al. [23] | 1994 | Pilot study | First demonstration that cetrorelix prevents premature LH surges during ovarian stimulation | | Olivennes et al. [5] | 2000 | Phase III RCT | Single-dose cetrorelix (3 mg) comparable to triptorelin depot agonist for IVF outcomes | | Albano et al. [6] | 2000 | Phase III RCT (European) | Cetrorelix antagonist protocol vs. buserelin agonist: comparable pregnancy rates with shorter treatment | | Kupker et al. [7] | 2002 | Clinical study | Cetrorelix 3 mg weekly for 8 weeks induced endometriosis regression in 60% of patients | | Felberbaum et al. [8] | 2007 | Phase II RCT | Cetrorelix reduced uterine fibroid volume by 15.6% in 4 weeks (vs. 5.1% placebo) | | Gonzalez-Barcena et al. [9] | 2008 | Phase II RCT | Cetrorelix improved IPSS by 3-4 units in symptomatic BPH; safe at all doses tested | | Al-Inany et al. [4] | 2016 | Cochrane review | GnRH antagonists vs. agonists in IVF: comparable live births, lower OHSS with antagonists (OR 0.43) | | Wang et al. [19] | 2025 | Retrospective cohort (n=15,617) | Cetrorelix superior to ganirelix for LH surge control (4.9% vs. 7.6%) and OHSS rates (0.4% vs. 1.1%) |

Dose-Response Relationships

LH Suppression Dose-Response

Cetrorelix demonstrates a remarkably clear dose-dependent pharmacodynamic profile that has been characterized in both healthy volunteers and IVF patients [3][13][14][23]:

Single-dose LH suppression in healthy volunteers (Pechstein et al. 2000):

| Dose (mg SC) | LH Suppression Onset | Duration of Significant LH Suppression | Nadir LH (% of baseline) | |---|---|---|---| | 0.1 | ~2-4 hours | ~12-18 hours | ~40-50% | | 0.25 | ~1-2 hours | ~24-36 hours | ~20-30% | | 0.5 | ~1-2 hours | ~48-60 hours | ~10-20% | | 1 | ~1 hour | ~72-84 hours | less than 10% | | 3 | ~1 hour | ~96-120 hours (4-5 days) | less than 5% | | 5 | ~1 hour | ~120-144 hours | less than 5% |

The dose-response curve is approximately log-linear between 0.1 and 3 mg, with a ceiling effect above 3 mg where further dose increases extend duration but do not further suppress LH nadir. This pharmacodynamic profile directly informed the two approved dosing protocols [3][13]:

• 0.25 mg daily: The minimum effective dose for complete LH surge prevention in IVF. Produces 24-36 hours of suppression per dose; daily administration maintains continuous LH blockade. At steady state (after 3-4 daily doses), accumulation extends the effective half-life from ~5 hours (single dose) to ~20.6 hours [3][13].
• 3 mg single dose: Provides 96+ hours of effective LH suppression, enabling a "single injection" protocol. In Phase 3 trials, approximately 73% of patients required only this single injection (no additional 0.25 mg doses before hCG trigger) [3][5].

Half-Life Dose Dependency

The dramatic dose-dependent half-life of cetrorelix is one of its most pharmacokinetically unusual features [3][13]:

| Dose | Half-life | Mechanism of Extended Half-life | |---|---|---| | 0.25 mg single dose | ~5 hours | Rapid absorption and distribution; minimal depot effect | | 0.25 mg multiple doses | ~20.6 hours | Accumulation kinetics; tissue binding reservoir | | 3 mg single dose | ~62.8 hours | Subcutaneous depot effect at higher injection volume; slower absorption from injection site |

The 12-fold difference in half-life between 0.25 mg and 3 mg single doses likely reflects concentration-dependent formation of a semi-depot at the subcutaneous injection site at the higher dose. At 3 mg, the local peptide concentration exceeds the aqueous solubility threshold, creating a transient precipitate that dissolves slowly, producing sustained drug release [3][13]. This depot effect is less pronounced than that seen with degarelix (which forms a stable gel depot at 40-80 mg/mL concentrations) but is clinically sufficient to provide 4-5 days of LH suppression from a single injection.

FSH Suppression Dose-Response

Cetrorelix preferentially suppresses LH over FSH, a pharmacologically advantageous property for IVF [3][14][23]:

• At 0.25 mg daily, LH is suppressed by approximately 70-80% while FSH decreases by only 30-50%
• This differential suppression occurs because FSH secretion is partially gonadotropin-independent (constitutive secretion) and has a longer circulatory half-life than LH
• The residual FSH supports ongoing follicular development during ovarian stimulation, while LH suppression prevents premature ovulation

Testosterone and Estradiol Suppression (Non-IVF Applications)

In men receiving cetrorelix for BPH or prostate indications [9][14]:

• 5 mg weekly for 4 weeks: Testosterone suppression to near-castrate levels (~50-80 ng/dL) by week 2; full castrate levels (at or below 50 ng/dL) in approximately 80% by week 4
• 10 mg weekly for 4 weeks: More rapid and complete testosterone suppression; castrate levels in greater than 90% by week 2
• PSA reduction: 30-45% decline from baseline in BPH patients over 4 weeks

In women with endometriosis [7]:

• 3 mg weekly for 8 weeks: Estradiol suppression to 30-60 pg/mL (the "therapeutic window" above the bone-protection threshold but below the endometriosis stimulation threshold)
• Partial rather than complete ovarian suppression, which may reduce vasomotor symptoms compared to GnRH agonists

Enhanced Safety Profile

Comprehensive Adverse Event Database

Cetrorelix has been administered to thousands of women in IVF cycles and to smaller cohorts in investigational studies for BPH, endometriosis, and fibroids. The overall safety profile is favorable [3][4][7][8][9]:

IVF indication (FDA-approved dosing):

| Adverse Event | Cetrorelix (0.25 mg or 3 mg) | GnRH Agonist Comparator | Significance | |---|---|---|---| | OHSS (any grade) | 0.4-3.5% | 5-8% | Significantly lower with antagonist protocols | | Severe OHSS | 0.3-1% | 2-3% | Significantly lower (OR 0.43 per Cochrane) | | Injection site reactions | 10-15% (mild, transient) | 5-10% | Slightly higher but clinically insignificant | | Nausea | 1-3% | 2-5% | Comparable | | Headache | 2-4% | 3-5% | Comparable | | Premature LH surge (protocol failure) | 4.9% (cetrorelix) vs 7.6% (ganirelix) | 1-2% (agonist long protocol) | Slightly higher but offset by shorter treatment | | Multiple pregnancy rate | Comparable to agonist protocols | Reference | No difference attributable to GnRH analog choice | | Congenital anomaly rate | Comparable to general IVF population | Reference | No teratogenic signal |

Histamine Release and Anaphylaxis Risk

The histamine-releasing potential of GnRH antagonists has been a persistent safety concern since the earliest compounds in this class caused clinically significant mast cell degranulation [1][12][21]:

Histamine release hierarchy (from Debruyne et al. 2010, ex vivo human skin model):

| GnRH Antagonist | Relative Histamine Release | Clinical Consequence | |---|---|---| | Cetrorelix | Highest among modern antagonists | Rare clinical reactions at IVF doses (0.25-3 mg) | | Abarelix | Moderate-high | Contributed to withdrawal from US market | | Ganirelix | Moderate | Very rare clinical reactions | | Degarelix | Lowest | Minimal (designed to minimize mast cell interaction) |

Despite its relatively higher histamine-releasing potential in vitro, clinically significant histamine-mediated reactions with cetrorelix are rare at the low doses used in IVF (0.25-3 mg). The D-citrulline substitution at position 6 was the key structural modification that reduced histamine release from the clinically unacceptable levels seen with first-generation antagonists (which used D-arginine at position 6) to the clinically manageable levels of cetrorelix [1][12].

Post-marketing reports include rare cases of anaphylactoid reactions (urticaria, facial edema, dyspnea) and one case of severe anaphylaxis after repeated exposure. Patients with a history of allergic reactions should be observed for 30 minutes after the first injection [3].

OHSS Prevention Safety Advantage

The most clinically significant safety advantage of cetrorelix-based protocols is the reduction in OHSS risk [4][24][25]:

OHSS risk reduction mechanisms:

1. Shorter stimulation duration reduces cumulative estradiol exposure and follicular over-recruitment
2. Lower total gonadotropin requirement further reduces the intensity of ovarian stimulation
3. GnRH agonist trigger compatibility is the most impactful safety feature: when cetrorelix is used for LH suppression, final oocyte maturation can be triggered with a GnRH agonist bolus (e.g., leuprolide 1 mg or buserelin 0.5 mg) instead of hCG. The agonist trigger induces a self-limiting endogenous LH/FSH surge lasting only 24-36 hours (vs hCG's 5-7 day half-life), virtually eliminating the risk of severe early-onset OHSS [22][25]

ASRM guidelines (2023) recommend GnRH antagonist protocols for all high-risk patients: PCOS, high antral follicle count (greater than 14 total), prior OHSS, AMH greater than 3.5 ng/mL, or BMI below 20 [25].

Reproductive Safety and Pregnancy Outcomes

Long-term reproductive safety data for cetrorelix are reassuring [2][4][19]:

• No teratogenic signal: Birth defect rates in pregnancies conceived during cetrorelix-containing IVF cycles are comparable to those in GnRH agonist-based cycles and to general IVF population rates
• Neonatal outcomes: Birth weight, gestational age, Apgar scores, and NICU admission rates are comparable between antagonist and agonist IVF protocols (Cochrane review, 2016) [4]
• Pregnancy rates: Live birth rates are comparable between cetrorelix and GnRH agonist protocols across meta-analyses [2][4]
• Long-term child outcomes: Limited long-term follow-up data available, but no signal of adverse developmental effects has been identified

Contraindications and Special Populations

• Pregnancy (Category X): Cetrorelix may cause fetal harm; pregnancy must be excluded before treatment
• Severe renal impairment: Contraindicated due to reduced clearance and potential accumulation
• Hypersensitivity: Prior anaphylactic reaction to cetrorelix, GnRH, GnRH analogs, or mannitol
• Hepatic impairment: No dose adjustment required for mild-moderate impairment; limited data in severe hepatic disease
• Lactation: Contraindicated; unknown whether cetrorelix is excreted in human milk
• Geriatric patients: No approved indication in postmenopausal women

References

1. [1] (). . . DOI
2. [2] (). . . DOI
3. [3] (). . .
4. [4] (). . . DOI
5. [5] (). . . DOI
6. [6] (). . . DOI
7. [7] (). . . DOI
8. [8] (). . . DOI
9. [9] (). . . DOI
10. [10] (). . . DOI
11. [11] (). . . DOI
12. [12] (). . . DOI
13. [13] (). . . DOI
14. [14] (). . . DOI
15. [15] (). . .
16. [16] (). . . DOI
17. [17] (). . . DOI
18. [18] (). . .
19. [19] (). . . DOI
20. [20] (). . . DOI
21. [21] (). . . DOI
22. [22] (). . . DOI
23. [23] (). . . DOI
24. [24] (). . . DOI
25. [25] (). . . DOI